German Central Committee against Tuberculosis (DZK), Berlin, Germany.
Independent Consultant & Department of Healthcare Management, Technical University of Berlin, Berlin, Germany.
Euro Surveill. 2024 Apr;29(17). doi: 10.2807/1560-7917.ES.2024.29.17.2400211.
The BPaLM regimen (bedaquiline, pretomanid, linezolid and moxifloxacin) recently recommended by the World Health Organization offers short, safe, and effective treatment for multidrug-resistant/rifampicin-resistant tuberculosis (TB). In a survey with national TB focal points in 18 central and western European countries to explore barriers for the implementation of BPaLM, only three reported full availability of pretomanid, a necessary component of this regimen. Implementation barriers included financing and procurement. Solutions on national and supranational level are needed to guarantee universal access.
世界卫生组织最近推荐的 BPaLM 方案（贝达喹啉、普托马尼德、利奈唑胺和莫西沙星）为耐多药/利福平耐药结核病（TB）提供了一种短期、安全和有效的治疗方法。在一项针对 18 个中、西欧国家国家结核病重点机构的调查中，为探索实施 BPaLM 的障碍，只有三个国家报告了普托马尼德的全面供应，这是该方案的必要组成部分。实施障碍包括融资和采购。需要在国家和超国家层面上找到解决方案，以确保普及。
